Drug X which inhibit the binding of RANKL to its receptor (RANK) in osteoporosis:
Teriparatide
Alendronate
Denosumab
Estrogen
Ans. C. DenosumabOsteoclasts express RANK receptor which on stimulation causes resorption of bone. Denosumab is monoclonal antibody which inhibit the binding of ligand to the receptor and thus play a role in osteoporosis.
Endocrinology